Immuron and US Department of Defense look to develop silver bullet for gastro infections

Biopharmaceutical company Immuron (ASX: IMC) is making significant territorial advances in its mission to develop and market a range of oral immunotherapeutics for the treatment of gut mediated pathogens. https://smallcaps.com.au/immuron-us-department-defense-develop-silver-bullet-gastro-infections/

This category is empty! Please try another category or use our search function to find what you are looking for. If you require further assistance please contact us.